金河生物科技股份有限公司 关于控股股东部分股份质押延期购回的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份办理了股票质押式回购交易延期购回业务。具体事项如下： 一、本次股东股票质押式回购交易延期购回基本情况 金河控股于近日办理了股份质押延期手续，将部分质押股份购回日延期。本 次股份质押延期购回的主要原因是其根据自身资金需求所做出的安排，不涉及新 增融资。详见下表： | | 是否为控 股股东或 | | 占其所 | 占公司 | 是否 | 是否为 | | | 延期购 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | 本次质押数 | | | | | 质押开始 | 质押到 | | | 质押 | | 名称 | 第一大股 | 量（股） | 持股份 | 总股本 | 为限 | 补充 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [6][7]. Core Views - The company is a leading player in veterinary antibiotics, specifically in the production of veterinary gentamicin, and is expanding its vaccine business to drive new growth [6][17]. - The company has shown steady revenue growth with a CAGR of 6.45% from 2018 to 2024, and a significant increase in Q1 2025 revenue driven by new production capacity and improved market conditions [6][25]. - The report highlights the potential for increased demand for veterinary drugs and vaccines due to improved profitability in the livestock sector, which is expected to drive recovery in the market [6][33]. Summary by Sections 1. Company Overview - The company, established in 1990, has become a global leader in veterinary gentamicin and has diversified into veterinary vaccines and other related fields [6][17]. - The company has a strong market position with nearly 70% market share in gentamicin production and is expanding its production capacity [6][25]. 2. Animal Health - The report emphasizes the recovery of vaccine and veterinary drug demand driven by improved profitability in the livestock sector [6][33]. - The veterinary pharmaceutical market is characterized by intense competition and product homogeneity, but leading companies are expected to gain market share through innovation and improved service [6][9]. 3. "Veterinary Drugs + Vaccines" Strategy - The company is expanding its vaccine portfolio, with significant products in the pipeline, including swine and ruminant vaccines [6][33]. - The report notes the strategic partnerships with universities to enhance research and development capabilities [6][33]. 4. Financial Forecast and Valuation - The company is projected to achieve revenues of 27.22 billion, 31.37 billion, and 36.28 billion yuan from 2025 to 2027, with corresponding net profits of 1.78 billion, 2.63 billion, and 3.41 billion yuan [7][8]. - The current stock price corresponds to a PE ratio of 27X for 2025, which is below the average of comparable companies [7][8]. 5. Key Assumptions - The report assumes a 20% revenue growth for veterinary pharmaceuticals and biological products from 2025 to 2027, with higher margins expected for vaccine products [8][9].

Investment Rating - The industry rating is "Recommended" [3] Core Insights - The report highlights that the sentiment in the pork market is supporting an upward shift in pork prices, with the average price for external three-line pigs at 14.20 CNY/kg, reflecting a week-on-week increase of 1.43% [2][12] - The report emphasizes the importance of increasing soybean and oilseed production, with a focus on enhancing yield through advanced agricultural practices and the promotion of genetically modified varieties [1][11] - The report suggests that while short-term consumer demand is recovering, supply remains relatively loose, but medium to long-term projections indicate that pork prices may exceed expectations in the second half of 2025 due to slow recovery in production capacity [2][12] Summary by Sections Planting Industry Chain - The Ministry of Agriculture and Rural Affairs held a meeting to discuss the production and demand situation for soybeans and oilseeds, emphasizing the need to enhance production capacity and implement key measures for yield improvement [1][11] - The report identifies potential beneficiaries in the planting sector, including Beidahuang and Suqian Agricultural Development, and recommends companies with a strong first-mover advantage in the seed industry such as Dabeinong and Longping High-Tech [1][11] Swine Farming - The average price of external three-line pigs is reported at 14.20 CNY/kg, with a significant increase in slaughter volume and consumer demand noted [2][12] - The report indicates that the number of breeding sows has decreased slightly, and the profitability of self-breeding operations has turned positive, suggesting a potential for recovery in the swine sector [2][12] - Recommended stocks in the swine farming sector include companies like Muyuan Foods, Wens Foodstuff Group, and DeKang Agriculture [2][12] Key Agricultural Product Data Tracking - Corn: The average price is 2412.94 CNY/ton, with a week-on-week increase of 0.54% [26] - Wheat: The average price is 2440.61 CNY/ton, with a week-on-week increase of 0.46% [29] - Soybeans: The average price is 3946.32 CNY/ton, with a week-on-week increase of 0.21% [40] - Cotton: The average price is 14760.00 CNY/ton, with a week-on-week increase of 0.15% [45] Feed and Vitamin Prices - The average price of pig feed is reported at 2.69 CNY/kg, with a week-on-week increase of 0.75% [51] - Vitamin E prices have decreased by 10.02% to 80.80 CNY/kg [51][59]

金河控股于近日办理了股份质押延期手续，将部分质押股份购回日延期。本 次股份质押延期购回的主要原因是其根据自身资金需求所做出的安排，不涉及新 增融资。详见下表： | | 是否为控 股股东或 | | | 占其所 | 占公司 | 是否 | 是否为 | | | 延期购 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | | | 本次质押数 | | | | | 质押开始 | 质押到 | | | 质押 | | 名称 | 第一大股 | | 量（股） | 持股份 | 总股本 | 为限 | 补充质 | 日期 | 期日 | 回后到 | 质权人 | 用途 | | | 东及其一 | | | 比例 | 比例 | 售股 | 押 | | | 期日 | | | | | 致行动人 | | | | | | | | | | | | | 金 河 | | 是 | 24,250,000 | 10.03% | 3.14% | 否 | 否 | 2024 年 6 月 17 日 | 2025年 6 月 17 日 | 2026 年 ...

Group 1 - The grain concept sector rose by 1.30%, ranking 9th among concept sectors, with 23 stocks increasing in value, including Qiu Le Seed Industry, Kang Nong Seed Industry, and Shen Nong Seed Industry, which rose by 11.99%, 10.91%, and 8.29% respectively [1] - The top gainers in the grain concept sector included Jinhe Biological, with a net inflow of 67.34 million yuan, followed by Denghai Seed Industry, Longping High-Tech, and COFCO Technology, with net inflows of 38.17 million yuan, 36.26 million yuan, and 35.14 million yuan respectively [2][3] - The main capital inflow ratios were led by Denghai Seed Industry, Jingliang Holdings, and Jinhe Biological, with net inflow rates of 13.59%, 12.33%, and 8.93% respectively [3] Group 2 - The grain concept sector saw a net inflow of 189 million yuan, with 22 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow [2] - The stocks with the highest trading turnover included Jinhe Biological at 15.46%, Denghai Seed Industry at 3.15%, and Longping High-Tech at 3.10% [3][4] - The overall performance of the grain concept sector was positive, with several stocks showing significant gains, while some stocks like Weiwei Co., Lianhua Holdings, and Luoping Zinc Electric experienced declines of 2.92%, 2.06%, and 1.89% respectively [1][5]

Core Viewpoint - The animal vaccine sector has shown a positive performance with a 1.29% increase, ranking 10th among concept sectors, driven by significant gains in stocks like *ST Xianfeng, Kexing Pharmaceutical, and Jinhai Biological [1][2]. Group 1: Sector Performance - As of June 10, the animal vaccine concept saw 16 stocks rise, with *ST Xianfeng hitting the daily limit, while Kexing Pharmaceutical and Jinhai Biological increased by 6.40% and 4.72% respectively [1]. - The sector's performance is part of a broader market trend, with various other concepts also experiencing fluctuations, such as the transgenic sector rising by 3.15% [2]. Group 2: Capital Flow - The animal vaccine sector attracted a net inflow of 150 million yuan, with 10 stocks receiving significant capital inflows, and 7 stocks exceeding 10 million yuan in net inflow [2]. - Jinhai Biological led the net inflow with 67.34 million yuan, followed by Kexing Pharmaceutical and Dabeinong with 36.46 million yuan and 21.42 million yuan respectively [2][3]. Group 3: Stock-Specific Data - The top stocks by net capital inflow ratio included *ST Xianfeng at 10.73%, Kexing Pharmaceutical at 9.86%, and Jinhai Biological at 8.93% [3]. - The trading volume and turnover rates for key stocks indicate active trading, with Jinhai Biological showing a turnover rate of 15.46% and Kexing Pharmaceutical at 3.35% [3].

金河生物科技股份有限公司章程 金河生物科技股份有限公司 章 程 （二〇二五年六月修订） | 第一章 总则 3 | | --- | | 第二章 经营宗旨和范围 4 | | 第三章 股份 4 | | 第一节 股份发行 4 | | 第二节 股份增减和回购 7 | | 第三节 股份转让 8 | | 第四章 股东和股东大会 9 | | 第一节 股东 9 | | 第二节 股东大会的一般规定 11 | | 第三节 股东大会的召集 14 | | 第四节 股东大会的提案与通知 15 | | 第五节 股东大会的召开 17 | | 第六节 股东大会的表决和决议 19 | | 第五章 董事会 24 | | 第一节 董事 24 | | 第二节 董事会 27 | | 31 第六章 总经理及其他高级管理人员 | | 第七章 监事会 32 | | 第一节 监事 32 | | 第二节 监事会 33 | | 第八章 财务会计制度、利润分配和审计 34 | | 第一节 财务会计制度 34 | | 第二节 内部审计 37 | | 第三节 会计师事务所的聘任 37 | | 第九章 通知和公告 38 | | 第一节 通知 38 | | 第二节 公告 3 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-048 金河生物科技股份有限公司 关于控股子公司为公司提供担保额度预计的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 特别提示： 1、金河生物科技股份有限公司（以下简称"公司"、"金河生物"）及子 公司累计对外担保金额（包含本次预计新增担保）超过公司最近一期经审计净资 产50%。 2、公司及子公司未对合并报表范围外的公司提供担保。 3、公司及子公司未发生逾期担保、涉及诉讼的担保及因担保被判决败诉而 应承担损失的情况。 一、担保情况概述 公司于2025年6月10日召开第六届董事会第二十六次会议，以9票同意，0票 反对，0票弃权审议通过了《关于控股子公司为公司提供担保额度预计的议案》。 为满足公司正常生产经营的资金需求，公司控股子公司金河佑本生物制品有限公 司（以下简称"金河佑本"）拟为金河生物在国家开发银行内蒙古自治区分行融 资提供担保，担保最高额度为不超过20,000万元，担保期限预计为不超过2年， 占公司2024年经审计归属于母公司所有者净资产的比例为8.90%，为连带责任保 ...

证券代码：002688 证券简称：金河生物 公告编号：2025-049 金河生物科技股份有限公司 关于增加公司经营范围并修改《公司章程》的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于 2025 年 6 月 10 日召开 第六届董事会第二十六次会议，审议通过了《关于增加公司经营范围并修改<公 司章程>的议案》。现将具体情况公告如下： 一、修订《公司章程》和经营范围变更说明 为满足公司经营发展需要，同时根据市场监督管理部门现行规定，公司拟对 经营范围进行变更，在原经营范围中增加：互联网信息服务；信息技术咨询服务。 根据《中华人民共和国公司法》《中华人民共和国证券法》及《深圳证券交易所 股票上市规则》等相关法律法规及规范性文件的规定，结合公司实际情况，公司 董事会同意对《公司章程》部分条款进行修订。 具体内容以市场监督管理部门的核准登记为准。 二、《公司章程》修订情况 根据上述事项，公司拟对《公司章程》相关内容进行修订。具体如下： | 序号 | 修订前 | 修订后 | | --- | --- | - ...

证券代码：002688 证券简称：金河生物 公告编号：2025-050 金河生物科技股份有限公司 关于召开 2025 年第三次临时股东大会通知的公告 （2）网络投票时间：2025 年 6 月 26 日 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 一、召开会议的基本情况 1、股东大会届次：2025 年第三次临时股东大会 2、会议召集人：金河生物科技股份有限公司（以下简称"公司"）董事 会 3、会议召开的合法、合规性：公司于 2025 年 6 月 10 日召开了第六届董 事会第二十六次会议，会议决定于 2025 年 6 月 26 日召开公司 2025 年第三次 临时股东大会。本次股东大会的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》等的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 6 月 26 日下午 14:30 （1）2025 年 6 月 19 日下午收市后在中国证券登记结算有限责任公司深圳 分公司登记在册的公司全体股东均有权出席股东大会，并可以以书面形式委托 代理人出席会议和参加表决，该股东代理人 ...